Dhanuka Agritech Limited reported a 34.6% year-on-year decline in net profit to ₹363.04 crore for the quarter ended June 30, 2026 (Q1FY27), as delayed monsoon onset in key agricultural regions postponed sowing activities and suppressed product demand. Revenue from operations contracted by 12.6% to ₹4,619.28 million, while EBITDA fell 33.9% to ₹550.10 million. Despite the headwinds, the company’s debt-free balance sheet remains strong, and management reaffirmed its commitment to long-term growth drivers including a new manufacturing facility in Nagpur.

The results were discussed during an analysts’ and investors’ call hosted by Antique Stock Broking Limited on August 3, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The Board of Directors approved the unaudited financial results and declared a final dividend of 100%, amounting to ₹2 per equity share, at its meeting held on the same day. Statutory auditors S S Kothari Mehta & Co. LLP reviewed the financial statements.

Financial Performance Overview

Total income decreased to ₹4,707.91 million from ₹5,363.32 million in Q1FY26. EBITDA margins contracted to 11.91% from 15.75%, reflecting price competition and weaker domestic demand. Gross margins slipped to 35.16% from 36.03%. Earnings per share (EPS) settled at ₹8.06, down from ₹12.31 in the corresponding prior period.

Expenses totaled ₹4,222.17 million, down 8.6% year-on-year. Cost of materials consumed decreased to ₹2,871.33 million from ₹3,614.59 million. Tax expenses were recorded at ₹1,221.92 million, compared to ₹1,904.22 million in Q1FY26.

Strategic Initiatives and Operational Updates

The company is proceeding with a new pesticide manufacturing facility in the Butibori industrial zone of Nagpur, Maharashtra. The plant will have an annual capacity of 23,000 metric tons and is expected to be operational by April 2028. The total estimated outlay is up to ₹200 crore, with CAPEX of over ₹100 crore expected to be incurred in FY27-28. Financing will be sourced through internal accruals and/or debt. Management highlighted that the facility will be significantly automated to reduce labor dependencies and meet global safety standards.

In the international segment, Dhanuka has acquired Iprovalicarb and Triadimenol variants from Bayer for global markets. While revenue from these products was nominal in Q1FY27, management indicated that major turnover is expected from September onwards, particularly for grape season products. Royalty income from Bayer products stood at approximately ₹4 crore, significantly lower than the prior year.

What the Numbers Show

A notable divergence exists between revenue contraction and expense management. While revenue fell by 12.6%, total expenses declined by only 8.6%, leading to a sharper drop in profitability. CFO V. K. Bansal attributed this to fixed costs incurred in anticipation of the season, which could not be scaled down proportionally. Furthermore, volume decline (12.7%) closely mirrored value decline (12.56%), indicating that price hikes attempted in April due to geopolitical tensions did not sustain through May and July. The company’s guidance for FY27 suggests lower single-digit revenue growth and an approximate 200 basis point decline in EBITDA, signaling continued near-term headwinds despite a strong balance sheet.

Dhanuka Agritech Limited shareholders approved all seven resolutions at the company’s 41st Annual General Meeting (AGM) held on August 3, 2026, including critical equity incentive plans and director reappointments. The most significant outcomes were the approval of the Dhanuka Employee Stock Option Plan 2026 (ESOP 2026) and the Dhanuka Stock Appreciation Rights Plan 2026 (SAR 2026), both passed as special resolutions. These approvals enable the company to grant equity-linked incentives to eligible employees, aligning long-term employee interests with shareholder value creation despite notable dissent on the ESOP proposal from institutional investors.

The meeting, conducted via Video Conferencing (VC) in compliance with Ministry of Corporate Affairs (MCA) and Securities and Exchange Board of India (SEBI) circulars, commenced at 11:00 A.M. IST. A total of 95 members attended, satisfying the quorum under Section 103 of the Companies Act, 2013. Mahendra Kumar Dhanuka, Chairman, chaired the proceedings, while Rahul Dhanuka, Managing Director, welcomed attendees. The Audited Financial Statements for FY26, along with reports from the Board and Statutory Auditor M/s. S.S. Kothari Mehta & Company LLP, were adopted.

Voting Results and Shareholder Sentiment

The consolidated scrutinizer’s report by M/s. VAPN & Associates, dated August 4, 2026, details the voting patterns across all resolutions. While promoter group support was unanimous across all items, public institutional investors showed significant divergence on the ESOP plan. The remote e-voting facility was provided by National Securities Depositories Limited (NSDL), with voting open from July 31 to August 2, 2026.

Governance and Compliance Details

The AGM adhered to regulatory requirements under Section 108 of the Companies Act, 2013, Rule 20 of the Companies (Management and Administration) Rules, 2014, and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The cut-off date for voting eligibility was July 27, 2026, with 42,503 shareholders on record. The promoter group held 3,11,21,902 shares, representing approximately 69.8% of the total equity, and voted unanimously in favor of all resolutions.

Harsh Dhanuka and Ashish Saraf were reappointed as Executive Directors after retiring by rotation. The Board also sought ratification for the remuneration payable to the company’s Cost Auditors. Independent Directors Satish Kumar Gupta, Sanjay Saxena, Sanjiv Goel, Namrata Gupta, and Bajrang Lal Bajaj ensured robust oversight during the proceedings. The e-voting option remained open for 15 minutes post-meeting for members who had not yet voted.

What the Numbers Show

The voting data reveals a clear split in shareholder sentiment regarding employee compensation structures. While the SAR 2026 plan received near-universal support (98.86%), the ESOP 2026 plan faced substantial opposition from public institutions, which voted against it with 93.22% dissent. This suggests institutional investors may view stock options as more dilutive or less aligned with immediate performance metrics compared to stock appreciation rights. Conversely, the reappointment of Harsh Dhanuka saw minor dissent from public institutions (0.56% against), indicating specific concerns about individual director tenure or performance rather than a broad governance issue.